Novartis' Signature speeds up clinical trials
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Bristol Pushes Pedal To Metal In Immuno-Oncology Combo Testing
Bristol's early development lead exec Mike Burgess explains how the company is embracing adaptive trial design to rapidly test combinations of immuno-oncology drugs old and new, plus targeted agents.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.